Published in Nat Med on September 21, 2015
Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev (2016) 1.13
Multiplexed pancreatic genome engineering and cancer induction by transfection-based CRISPR/Cas9 delivery in mice. Nat Commun (2016) 1.00
Exploiting the Epigenome to Control Cancer-Promoting Gene-Expression Programs. Cancer Cell (2016) 0.98
Targeting bet bromodomain proteins in solid tumors. Oncotarget (2016) 0.89
HDAC1 and HDAC2 integrate the expression of p53 mutants in pancreatic cancer. Oncogene (2016) 0.83
BET Bromodomain Proteins Brd2, Brd3 and Brd4 Selectively Regulate Metabolic Pathways in the Pancreatic β-Cell. PLoS One (2016) 0.83
An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer. Nat Commun (2017) 0.82
Epigenetic therapy in gastrointestinal cancer: the right combination. Therap Adv Gastroenterol (2016) 0.81
Strategically targeting MYC in cancer. F1000Res (2016) 0.81
Coordination of stress signals by the lysine methyltransferase SMYD2 promotes pancreatic cancer. Genes Dev (2016) 0.81
The promise of epigenomic therapeutics in pancreatic cancer. Epigenomics (2016) 0.80
Kras(G12D) induces EGFR-MYC cross signaling in murine primary pancreatic ductal epithelial cells. Oncogene (2015) 0.79
Screening of Conditionally Reprogrammed Patient-Derived Carcinoma Cells Identifies ERCC3-MYC Interactions as a Target in Pancreatic Cancer. Clin Cancer Res (2016) 0.79
Epigenetics: Place your BETs. Nat Rev Cancer (2015) 0.78
Actionable Intelligence Provided by Pancreatic Cancer Genomic Landscape: Are Targets for Curative Therapy On The Map? Transl Cancer Res (2016) 0.78
Epigenetic blockade of neoplastic transformation by bromodomain and extra-terminal (BET) domain protein inhibitor JQ-1. Biochem Pharmacol (2016) 0.78
A Platform for Rapid, Quantitative Assessment of Multiple Drug Combinations Simultaneously in Solid Tumors In Vivo. PLoS One (2016) 0.77
The CRISPR revolution and its impact on cancer research. Swiss Med Wkly (2015) 0.77
OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations. Oncotarget (2016) 0.76
Discovery and Optimization of a Selective Ligand for the Switch/Sucrose Nonfermenting-Related Bromodomains of Polybromo Protein-1 by the Use of Virtual Screening and Hydration Analysis. J Med Chem (2016) 0.76
Epigenetic polypharmacology: from combination therapy to multitargeted drugs. Clin Epigenetics (2016) 0.76
Epigenetic treatment of pancreatic cancer: is there a therapeutic perspective on the horizon? Gut (2016) 0.76
Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non-small Cell Lung Cancer. Cancer Discov (2017) 0.75
Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents. Cell Death Dis (2016) 0.75
EMPOWERING MULTI-COHORT GENE EXPRESSION ANALYSIS TO INCREASE REPRODUCIBILITY. Pac Symp Biocomput (2016) 0.75
The cis-regulatory switchboard of pancreatic ductal cancer. EMBO J (2016) 0.75
Stromal remodeling by the BET bromodomain inhibitor JQ1 suppresses the progression of human pancreatic cancer. Oncotarget (2016) 0.75
Re-engineering the Pancreas Tumor Microenvironment: A "Regenerative Program" Hacked. Clin Cancer Res (2017) 0.75
Stromal cues regulate the pancreatic cancer epigenome and metabolome. Proc Natl Acad Sci U S A (2017) 0.75
BET inhibitors block pancreatic stellate cell collagen I production and attenuate fibrosis in vivo. JCI Insight (2017) 0.75
The BET bromodomain inhibitor exerts the most potent synergistic anticancer effects with quinone-containing compounds and anti-microtubule drugs. Oncotarget (2016) 0.75
Therapy: Targeting chromatin remodelling proteins to treat pancreatic cancer. Nat Rev Gastroenterol Hepatol (2015) 0.75
The miR-25-93-106b cluster regulates tumor metastasis and immune evasion via modulation of CXCL12 and PD-L1. Oncotarget (2017) 0.75
Gene expression profiling of patient-derived pancreatic cancer xenografts predicts sensitivity to the BET bromodomain inhibitor JQ1: implications for individualized medicine efforts. EMBO Mol Med (2017) 0.75
Pancreatic cancer: from bench to bedside. Ann Transl Med (2016) 0.75
Epigenetic Regulation of the Epithelial to Mesenchymal Transition in Lung Cancer. Cancers (Basel) (2017) 0.75
CRISPR/Cas9: Transcending the Reality of Genome Editing. Mol Ther Nucleic Acids (2017) 0.75
Tri-methylation of H3K79 is decreased in TGF-β1-induced epithelial-to-mesenchymal transition in lung cancer. Clin Epigenetics (2017) 0.75
Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A (2005) 167.46
A robust and high-throughput Cre reporting and characterization system for the whole mouse brain. Nat Neurosci (2009) 21.94
DNA targeting specificity of RNA-guided Cas9 nucleases. Nat Biotechnol (2013) 19.99
Selective inhibition of BET bromodomains. Nature (2010) 18.79
Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science (2009) 18.40
Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med (2013) 16.24
Genome engineering using the CRISPR-Cas9 system. Nat Protoc (2013) 15.98
Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell (2003) 15.43
Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev (2006) 15.09
BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell (2011) 14.34
Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell (2005) 14.21
Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res (2010) 12.96
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature (2011) 11.44
A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer (2011) 11.33
Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat Genet (2001) 9.55
Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell (2007) 8.47
Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell (2013) 8.37
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature (2012) 8.31
The role of the transcriptional regulator Ptf1a in converting intestinal to pancreatic progenitors. Nat Genet (2002) 8.28
Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev (2003) 8.27
Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev (2006) 8.26
Pancreatic cancer biology and genetics. Nat Rev Cancer (2002) 7.36
Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res (2014) 7.15
Pancreatic cancer. Annu Rev Pathol (2008) 6.96
Pancreatic adenocarcinoma. N Engl J Med (2014) 6.21
Production and purification of lentiviral vectors. Nat Protoc (2006) 6.01
Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc Natl Acad Sci U S A (2006) 5.90
Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes Dev (2006) 5.53
Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations. Cancer Res (2006) 4.83
Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nat Protoc (2009) 4.50
Protocols to detect senescence-associated beta-galactosidase (SA-betagal) activity, a biomarker of senescent cells in culture and in vivo. Nat Protoc (2009) 4.47
Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia. Cancer Cell (2012) 4.16
Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell (2011) 4.12
Analysis of C-MYC function in normal cells via conditional gene-targeted mutation. Immunity (2001) 4.09
Whole genomes redefine the mutational landscape of pancreatic cancer. Nature (2015) 4.01
Mutation detection using Surveyor nuclease. Biotechniques (2004) 3.72
Pancreatic epithelial plasticity mediated by acinar cell transdifferentiation and generation of nestin-positive intermediates. Development (2005) 3.57
Small-molecule inhibition of BRDT for male contraception. Cell (2012) 3.50
Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression. Cancer Cell (2011) 3.47
Ablation of the CDK inhibitor p57Kip2 results in increased apoptosis and delayed differentiation during mouse development. Genes Dev (1997) 3.45
Context-dependent transformation of adult pancreatic cells by oncogenic K-Ras. Cancer Cell (2009) 3.37
Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice. Nat Protoc (2009) 3.36
Oncogenic Kras activates a hematopoietic-to-epithelial IL-17 signaling axis in preinvasive pancreatic neoplasia. Cancer Cell (2014) 3.29
EGF receptor is required for KRAS-induced pancreatic tumorigenesis. Cancer Cell (2012) 3.19
Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models. Nat Biotechnol (2010) 3.15
Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proc Natl Acad Sci U S A (2009) 3.08
Stage-specific sensitivity to p53 restoration during lung cancer progression. Nature (2010) 3.03
Beta-catenin blocks Kras-dependent reprogramming of acini into pancreatic cancer precursor lesions in mice. J Clin Invest (2010) 2.90
Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. Cell (2014) 2.74
Pancreatitis-induced inflammation contributes to pancreatic cancer by inhibiting oncogene-induced senescence. Cancer Cell (2011) 2.56
Biology and management of pancreatic cancer. Gut (2007) 2.53
STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis. Cancer Res (2011) 2.35
Endogenous Myc maintains the tumor microenvironment. Genes Dev (2011) 2.16
IQGAP1 scaffold-kinase interaction blockade selectively targets RAS-MAP kinase-driven tumors. Nat Med (2013) 2.07
Functionally defined therapeutic targets in diffuse intrinsic pontine glioma. Nat Med (2015) 2.07
Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun (2015) 1.94
Rapid modelling of cooperating genetic events in cancer through somatic genome editing. Nature (2014) 1.86
Notch2 is required for progression of pancreatic intraepithelial neoplasia and development of pancreatic ductal adenocarcinoma. Proc Natl Acad Sci U S A (2010) 1.84
SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer. Nature (2014) 1.75
Chromatin immunoprecipitation (ChIP). Cold Spring Harb Protoc (2009) 1.69
PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies. Nature (2014) 1.60
Brg1 promotes both tumor-suppressive and oncogenic activities at distinct stages of pancreatic cancer formation. Genes Dev (2015) 1.58
Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer. Clin Cancer Res (2013) 1.56
A common rejection module (CRM) for acute rejection across multiple organs identifies novel therapeutics for organ transplantation. J Exp Med (2013) 1.47
Epigenetic down-regulation of CDKN1C/p57KIP2 in pancreatic ductal neoplasms identified by gene expression profiling. Clin Cancer Res (2005) 1.33
p48 subunit of mouse PTF1 binds to RBP-Jkappa/CBF-1, the intracellular mediator of Notch signalling, and is expressed in the neural tube of early stage embryos. Genes Cells (2001) 1.32
c-MYC activation in primary and metastatic ductal adenocarcinoma of the pancreas: incidence, mechanisms, and clinical significance. Mod Pathol (2002) 1.31
Miz1 is required for early embryonic development during gastrulation. Mol Cell Biol (2003) 1.29
Kras as a key oncogene and therapeutic target in pancreatic cancer. Front Physiol (2014) 1.19
A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas. Eur J Cancer (2014) 1.17
Predictive in vivo animal models and translation to clinical trials. Drug Discov Today (2012) 1.12
The cell cycle inhibitor p57(Kip2) promotes cell death via the mitochondrial apoptotic pathway. Cell Death Differ (2007) 1.04
Insights into the epigenetic mechanisms controlling pancreatic carcinogenesis. Cancer Lett (2012) 1.02
CDK inhibitor p57 (Kip2) is downregulated by Akt during HER2-mediated tumorigenicity. Cell Cycle (2013) 0.99
BET bromodomain inhibitors block growth of pancreatic cancer cells in three-dimensional collagen. Mol Cancer Ther (2014) 0.98
The BET bromodomain inhibitor JQ1 suppresses growth of pancreatic ductal adenocarcinoma in patient-derived xenograft models. Oncogene (2015) 0.97
Senescence-associated SIN3B promotes inflammation and pancreatic cancer progression. J Clin Invest (2014) 0.94
Intraductal delivery of adenoviruses targets pancreatic tumors in transgenic Ela-myc mice and orthotopic xenografts. Oncotarget (2013) 0.89
Triplication of a 21q22 region contributes to B cell transformation through HMGN1 overexpression and loss of histone H3 Lys27 trimethylation. Nat Genet (2014) 1.67
Intraductal papillary neoplasms of the bile duct: stepwise progression to carcinoma involves common molecular pathways. Mod Pathol (2013) 1.22
Acetylation site specificities of lysine deacetylase inhibitors in human cells. Nat Biotechnol (2015) 1.19
A subset of metastatic pancreatic ductal adenocarcinomas depends quantitatively on oncogenic Kras/Mek/Erk-induced hyperactive mTOR signalling. Gut (2015) 0.92
Targeting PI3K/mTOR Signaling Displays Potent Antitumor Efficacy against Nonfunctioning Pituitary Adenomas. Clin Cancer Res (2015) 0.81
Current Standard and Future Perspectives in First- and Second-Line Treatment of Metastatic Pancreatic Adenocarcinoma. Digestion (2016) 0.80
Multiparametric human hepatocellular carcinoma characterization and therapy response evaluation by hyperpolarized (13) C MRSI. NMR Biomed (2016) 0.77
GSK-3β Governs Inflammation-Induced NFATc2 Signaling Hubs to Promote Pancreatic Cancer Progression. Mol Cancer Ther (2016) 0.75
Krüppel-like Transcription Factor KLF10 Suppresses TGFβ-Induced Epithelial-to-Mesenchymal Transition via a Negative Feedback Mechanism. Cancer Res (2017) 0.75
A genetic roadmap of pancreatic cancer: still evolving. Gut (2017) 0.75